- Home
- MGLD vs STTK Comparison
MGLD vs STTK Comparison
Compare MGLD & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGLD
- STTK
- Stock Information
- Founded
- MGLD 1996
- STTK 2016
- Country
- MGLD United States
- STTK United States
- Employees
- MGLD N/A
- STTK N/A
- Industry
- MGLD Finance/Investors Services
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- MGLD Finance
- STTK Health Care
- Exchange
- MGLD Nasdaq
- STTK Nasdaq
- Market Cap
- MGLD 35.8M
- STTK 37.6M
- IPO Year
- MGLD N/A
- STTK 2020
- Fundamental
- Price
- MGLD $1.00
- STTK $0.96
- Analyst Decision
- MGLD
- STTK Hold
- Analyst Count
- MGLD 0
- STTK 4
- Target Price
- MGLD N/A
- STTK $3.00
- AVG Volume (30 Days)
- MGLD 12.6K
- STTK 116.5K
- Earning Date
- MGLD 05-08-2025
- STTK 07-31-2025
- Dividend Yield
- MGLD N/A
- STTK N/A
- EPS Growth
- MGLD N/A
- STTK N/A
- EPS
- MGLD N/A
- STTK N/A
- Revenue
- MGLD $31,205,000.00
- STTK $4,606,000.00
- Revenue This Year
- MGLD N/A
- STTK N/A
- Revenue Next Year
- MGLD N/A
- STTK N/A
- P/E Ratio
- MGLD N/A
- STTK N/A
- Revenue Growth
- MGLD N/A
- STTK 69.65
- 52 Week Low
- MGLD $0.70
- STTK $0.69
- 52 Week High
- MGLD $2.10
- STTK $4.99
- Technical
- Relative Strength Index (RSI)
- MGLD 58.23
- STTK 44.24
- Support Level
- MGLD $0.80
- STTK $0.95
- Resistance Level
- MGLD $1.04
- STTK $1.24
- Average True Range (ATR)
- MGLD 0.07
- STTK 0.08
- MACD
- MGLD 0.01
- STTK -0.02
- Stochastic Oscillator
- MGLD 77.67
- STTK 5.05
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.